<PAGE>
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

                                   (Mark One)

          [ X ]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended December 31, 2002

                                       OR

       [ ]TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT
                                    OF 1934

          From the transition period from ___________ to ____________.

                         Commission File Number 01-28911
                                                --------

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                      ------------------------------------
        (Exact name of small business issuer as specified in its charter)

                Colorado                               91-1869677
      ------------------------------         -------------------------------
     (State or other jurisdiction of        (IRS Employer Identification No.)
      incorporation or organization)


         20700 Ventura Boulevard, #227, Woodland Hills, California 91364
         ---------------------------------------------------------------
                    (Address of principal executive offices)

                                 (818) 227-9494
                                 --------------
                           (Issuer's telephone number)

                                       N/A
                                       ---
         (Former name, former address and former fiscal year, if changed
                               since last report)

         Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Exchange Act during the past
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days:

                                   Yes : No 9

As of February 14, 2003 7,855,500 shares of Common Stock of the issuer were
outstanding.


<PAGE>




PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                            CONDENSED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                        December 31,       September 30,
                                                                           2002                2002
                                                                       ---------------------------------
                                                                       (Unaudited)
<S>                                                                    <C>                   <C>
ASSETS                                                                 $        --           $        --
                                                                       ===========           ===========

               LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
  Accounts payable:
    Trade                                                              $    42,464           $    42,089
    Stein's Holdings, Inc.                                                  58,311                53,811
  Income tax payable                                                           800                   800
  Deposit on merger                                                         18,304                18,304
                                                                       -----------           -----------
    Total current liabilities                                              119,879               115,004
                                                                       -----------           -----------

Stockholders' equity (deficit):
  Preferred stock, $.01 par value, 500,000 shares
    authorized, no shares issued and outstanding                                --                    --
  Common stock, $.001 par value, 25,000,000 shares
    authorized:  7,855,500 shares issued and outstanding:                    7,855                 7,855
  Additional paid in capital                                             1,237,439             1,237,439
  Deficit accumulated during the development stage                      (1,365,173)           (1,360,298)
                                                                       -----------           -----------
    Total stockholders' equity (deficit)                                  (119,879)             (115,004)
                                                                       -----------           -----------
                                                                       $        --                    --
                                                                       ===========           ===========

</TABLE>


 See accompanying notes to interim condensed consolidated financial statements.




<PAGE>

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                       CONDENSED STATEMENTS OF OPERATIONS
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                       Inception
                                                                       Three Months Ended               through
                                                                          December 31,                December 31,
                                                                          ------------                -----------
                                                                    2002               2001               2002
                                                               ----------------   ----------------  -----------------
<S>                                                            <C>                <C>               <C>
Revenue                                                        $             -    $             -   $         9,578

Expenses:
  Development costs                                                          -                  -         1,264,236
  General and administrative                                             4,875             14,542           107,315
                                                               ---------------    ---------------   ---------------
                                                                         4,875             14,542         1,371,551
                                                               ---------------    ---------------   ---------------

Net loss before income taxes                                            (4,875)           (14,542)       (1,361,973)

Income taxes                                                                 -                  -             3,200
                                                               ---------------    ---------------   ---------------

Net loss                                                       $        (4,875)   $       (14,542)  $    (1,365,173)
                                                                ==============    ===============    ==============

Basic net loss per common share                                $          0.00    $          0.00
                                                                ==============    ===============

Weighted average shares outstanding                                  7,855,500          7,855,500
                                                                ==============    ===============
</TABLE>




 See accompanying notes to interim condensed consolidated financial statements.


<PAGE>

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                       CONDENSED STATEMENTS OF CASH FLOWS
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                       Inception
                                                                       Three Months Ended               through
                                                                          December 31,                December 31,
                                                                          -----------                 -----------
                                                                     2002               2001              2002
                                                                  -----------       -----------       -----------
Cash flows from operating activities:
<S>                                                               <C>               <C>               <C>
  Net loss                                                        $    (4,875)      $   (14,542)      $(1,365,173)
    Adjustments to reconcile net loss to net cash
    provided by (used in) operating activities:
      Depreciation and amortization                                        --                --            22,977
      Common stock issued for settlement of interest expense               --                --            12,900
      Common stock issued for services                                     --                --           217,900
      Loss on abandoned assets                                             --                --           120,387
      Gain on sale of assets                                               --                --              (500)
      Income from sale of abandoned assets                                 --                --            (9,578)
  Changes in operating assets and liabilities
    Accounts payable                                                    4,875            14,542           101,578
    Corporate income tax payable                                           --                --               800
    Deposit on merger                                                      --                --            18,304
                                                                  -----------       -----------       -----------
        Net cash provided by (used in) operating activities                --                --          (880,405)
                                                                  -----------       -----------       -----------

Cash flows from investing activities:
  Purchase of property and equipment                                       --                --           (87,314)
  Proceeds from the sale of equipment                                      --                --            15,078
                                                                  -----------       -----------       -----------
        Net cash provided by (used in) investing activities                --                --           (72,236)
                                                                  -----------       -----------       -----------

Cash flows from financing activities:
  Proceeds from notes payable                                              --                --           217,200
  Payments on notes payable                                                --                --           (20,000)
  Proceeds from the sale of common stock, net                              --                --           755,441
                                                                  -----------       -----------       -----------
        Net cash provided by financing activities                          --                --           952,641
                                                                  -----------       -----------       -----------

Net increase (decrease) in cash and cash equivalents                       --                --                --
Cash and cash equivalents at beginning of period                           --                --                --
                                                                  -----------       -----------       -----------
Cash and cash equivalents at end of period                        $        --       $        --                $-
                                                                  ===========       ===========       ===========

</TABLE>


 See accompanying notes to interim condensed consolidated financial statements.

<PAGE>

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                 NOTES TO INTERIM CONDENSED FINANCIAL STATEMENTS
                                December 31, 2002


Note 1:Presentation

The condensed balance sheet of the Company as of December 31, 2002, the related
condensed statements of operations and cash flows for the three months ended
December 31, 2002 and 2001 included in the condensed financial statements have
been prepared by the Company without audit. In the opinion of management, the
accompanying condensed financial statements include all adjustments (consisting
of normal, recurring adjustments) necessary to summarize fairly the Company's
financial position and results of operations. The results of operations for the
three months ended December 31, 2002 are not necessarily indicative of the
results of operations for the full year or any other interim period. The
information included in this Form 10-QSB should be read in conjunction with
Management's Discussion and Analysis and Financial Statements and notes thereto
included in the National Healthcare Technology, Inc.'s September 30, 2002 Form
10-KSB.



<PAGE>




Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS


This report contains forward looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. The Company's actual results could differ
materially from those set forth on the forward looking statements as a result of
the risks set forth in the Company's filings with the Securities and Exchange
Commission, general economic conditions, and changes in the assumptions used in
making such forward looking statements.

GENERAL

National Healthcare Technology, Inc. (the "Company") was organized February 29,
1996 as "Patriot Holding Corporation" and subsequently changed its name to
"National Healthcare Technology, Inc." on August 26, 1996. Between 1996 and
1999, the Company was unsuccessful in raising sufficient capital to begin and
complete a proposed double-blind study of an intravenous drug called Magkelate.
The Company did raise $1,000,000 which was used to pay its operating expenses
and general and administrative expenses as well as expenses related to starting
the double-blind study. Following its inability to raise capital and needing to
conserve its financial resources, the Company dismissed all of its employees in
early 1999. The developer of Magkelate passed away in the fall of 1999 and the
Magkelate patent has expired. Since 1999, the Company has been substantially
inactive. The Company is in the development stage as defined in Statement of
Financial Accounting Standards No. 7.

When used in this Form 10-QSB, the words "anticipate", "estimate", "expect",
"project" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to certain risks, uncertainties and
assumptions including the possibility that the Company's proposed plan of
operation will fail to generate projected revenues. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, estimated
or projected.

LIQUIDITY AND CAPITAL RESOURCES

The Company is in the development stage and since inception has experienced no
significant change in liquidity or capital resources or stockholders equity
other than the receipt of $1,000,000 from an offering conducted under Rule 504
of Regulation D in 1997. The Company's balance sheet as of December 31, 2002
reflects no assets and limited liabilities. Further, there exists no agreements
or understandings with regard to loan agreements by or with the Officers,
Directors, principals, affiliates or shareholders of the Company.

The Company is continuing to search for suitable merger candidates or other
businesses to become involved in so that it can commence operations and generate
revenues to continue paying its bills.

The Company will attempt to carry out its plan of business and hopes to enter
into a business combination with another entity. The Company cannot predict to
what extent its lack of liquidity and capital resources will hinder its business
plan prior to the consummation of a business combination.

RESULTS OF OPERATIONS

During the period from November 5, 1989 (inception) through December 31, 2002,
the Company engaged in limited operations and attempted to initiate its double
blind study of its drug, Magkelate. The Company received no revenues during this
period. The capital raised was expended for general office and administrative
expenses and the proposed double-blind study of Magkelate, which double-blind
study the Company was unable to start due to lack of capital.

For the quarter ended December 31, 2002, the Company had no revenue and its
expenses were $4,875, resulting in a net loss for the quarter of $4,875 compared
to no revenue and expenses of $14, for the quarter ended December 31, 2001 and a
net loss of $14,542.

The Company anticipates that until a business combination is completed with an
acquisition candidate, it will not generate revenue and may operate at a loss
after completing a business combination, depending upon the performance of the
acquired business.


<PAGE>


The Company will attempt to carry out its business plan as discussed above. The
Company cannot predict to what extent its lack of liquidity and capital
resources will hinder its business plan prior to the consummation of a business
combination.

NEED FOR ADDITIONAL FINANCING

The Company's existing capital will not be sufficient to meet the Company's cash
needs, including the costs of compliance with the continuing reporting
requirements of the Securities Exchange Act of 1934, as amended. Once a business
combination is completed, the Company's need for additional financing is likely
to increase substantially.
 No commitments to provide additional funds have been made by management or
other stockholders. Accordingly, there can be no assurance that any funds will
be available to the Company to allow it to cover its expenses.

The Company might seek to compensate providers of services by issuances of stock
in lieu of cash.


PART II - OTHER INFORMATION

Items No. 1, 2, 3, 4, 5 - Not applicable.

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

         a)  Exhibits
         27.1 Financial Data Schedule

         b) Reports on Form 8-K

         There were no reports on Form 8-K filed during the quarter for which
this report is filed.


                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.


                                          NATIONAL  HEALTHCARE  TECHNOLOGY, INC.


Date: February 14, 2002                   By: /s/ Charles Smith
                                              -------------------------
                                              Charles Smith
                                              CEO, CFO



<PAGE>




                              FORM OF CERTIFICATION
                       PURSUANT TO RULE 13a-14 AND 15d-14
              UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                  CERTIFICATION

I, Charles Smith, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of National Healthcare
Technology, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I am responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
         (a)designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;
         (b)evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days of the filing date of this quarterly
report (the "Evaluation Date"); and
         (c)presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;
5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
the registrant's board of directors (or persons performing the equivalent
functions):
         (a)all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize, and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
         (b)any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's internal
controls.
6. The registrant's other certifying officer and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: February 14, 2003                         /s/ Charles Smith
                                                ----------------------------
                                                Name:  Charles Smith
                                                Title: President


<PAGE>





                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of National Healthcare Technology, Inc.
on Form 10-QSB for the period ended December 31, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), each of
the undersigned, in the capacities and on the dates indicated below, hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operation of the Company.


/s/  Charles Smith
Charles Smith, President
Dated: February 13, 2003


<PAGE>